An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Cancer

In brief

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

Key facts

Study ID

NCT03351231

Run by

Bristol-Myers Squibb

People needed

7

Starts

2017-11-27

Expected to finish

2018-08-28

Last updated by the study team

2020-08-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measureable disease per RECIST v1.1
• Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Ability to swallow tablets
• Adequate bone marrow and organ function, as defined by the protocol

You may not qualify if…

• Participants with known or suspected CNS metastases, untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)
• Ocular melanoma
• Any significant acute or chronic medical illness
• Prior malignancy
• Other active malignancy requiring concurrent intervention
• Prior organ allograft or allogeneic bone marrow transplantation
• Participants with active, known, or suspected autoimmune disease
• Requirement for daily supplemental oxygen
• Uncontrolled or significant cardiovascular disease
• Pre-existing liver disease
• Gastrointestinal disease known to interfere with absorption
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• University Of Alabama At Birmingham — Birmingham, Alabama, United States
• Hoag Memorial Hospital Presbyterian — Los Angeles, California, United States
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Local Institution — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.